Ads
related to: crispr therapeutics stock price today
Search results
Why CRISPR Therapeutics Stock Is Jumping Again Today
Motley Fool· 7 months agoShares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more...
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Zacks via Yahoo Finance· 1 week agoCRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So,...
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Zacks via Yahoo Finance· 2 years agoCRISPR Therapeutics AG (CRSP) closed at $50.84 in the latest trading session, marking a -0.88% move...
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
Motley Fool via Yahoo Finance· 6 months agoCRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year -- and for good reason. The...
Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take.
Motley Fool· 7 months agoCRISPR Therapeutics (NASDAQ: CRSP) has reached a very exciting point in its story. The biotech...
If You Invested $10,000 in CRISPR Therapeutics In 2020, This Is How Much You Would Have Today
Motley Fool· 1 year agoGrowth stocks took off during 2020 amid the early stages of the pandemic. One of the stocks that...
Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Simply Wall St. via Yahoo Finance· 11 months agoKey Insights CRISPR Therapeutics' estimated fair value is US$64.30 based on 2 Stage Free Cash Flow...
Is CRISPR Therapeutics a Buy in the New Bull Market?
Motley Fool via Yahoo Finance· 4 months agoCRISPR Therapeutics (NASDAQ: CRSP) soared 54% last year as growth stocks rallied and the company itself moved toward an important milestone: the approval...
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment
Investor's Business Daily· 8 months agoCrispr Therapeutics is facing its make-or-break moment as experts point to a pivotal decision in...
Crispr Therapeutics Stock Sinks Despite FDA Approval
Schaeffer's Investment Research via Yahoo Finance· 6 months agoCrispr Therapeutics AG (NASDAQ:CRSP) stock is down 7.2% to trade at $59.89 at last check, despite its gene therapy treatment for sickle cell disease in...
